GET DAILY SIGNALSPacira BioSciences (PCRX) Q3 Earnings Preview as Viatris Acquisition Nears
Key Takeaways
- Pacira BioSciences (PCRX) is expected to report third-quarter 2026 results after the market close on November 5, 2026, covering the fiscal quarter ended September 30, 2026.
- Analysts' consensus estimates point to adjusted earnings per share (EPS) near $0.73 on revenue of roughly $182.9 million, compared with $0.70 in EPS and $179.5 million in revenue a year earlier.
- The report lands in the shadow of a definitive agreement for Viatris (VTRS) to acquire Pacira for $36.50 per share in cash, a deal valued at about $1.65 billion and expected to close by the end of November 2026.
- Investors will focus on EXPAREL volume trends, momentum in ZILRETTA and iovera, and any updated commentary on full-year 2026 guidance, which management lowered in August to $735 million–$760 million in revenue.
- Pipeline milestones, including the Phase 2 readout for the PCRX-201 gene therapy in knee osteoarthritis, remain secondary catalysts worth watching around the pending transaction.
- For more detail on Pacira's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages available on Tickeron.
- Discover automated trading ideas and market opportunities by exploring Tickeron's Trending AI Robots.
Why This Quarter Matters
Pacira BioSciences stands out in non-opioid pain management through its flagship product EXPAREL, a long-acting local anesthetic for postsurgical pain, along with ZILRETTA for knee osteoarthritis and the iovera cold-therapy system. This upcoming earnings release provides an important update on commercial progress just before the company integrates into Viatris. From what I see, Pacira has beaten consensus EPS estimates in five of the last eight quarters, with the most recent result showing $0.73 per share in Q2 2026 against a $0.65 estimate. Management reduced its full-year 2026 revenue outlook in August to a range of $735 million to $760 million, which fell short of prevailing Street views at the time, so this report serves as a useful checkpoint on the core business trajectory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Projecting
Wall Street consensus for the third quarter of 2026 calls for adjusted EPS of approximately $0.73 on revenue of about $182.9 million, based on data from MarketBeat. That compares to the prior-year quarter when the company delivered adjusted EPS of $0.70 on revenue of $179.52 million. Estimates differ somewhat across sources due to variations in GAAP versus non-GAAP treatments, but the overall expectation points to relatively flat to low-single-digit revenue growth. Beyond the top-line numbers, attention will center on EXPAREL volume trends, which have benefited from separate Medicare reimbursement under the NOPAIN Act implemented in early 2025. Updates on ZILRETTA and iovera uptake, operating margins, and any revision to full-year revenue guidance will also draw scrutiny. The stock has historically moved on earnings beats or guidance changes, yet the pending all-cash deal at $36.50 per share now keeps the price anchored near the transaction value.
Market Sentiment and Deal Dynamics
Investor focus on PCRX has centered more on the acquisition than on any single quarter’s fundamentals. On October 8, 2026, Viatris announced it would buy all outstanding Pacira shares for $36.50 in cash, placing a total value of roughly $1.65 billion on the company. The tender offer began on October 30, with closing anticipated by the end of November. As a result, shares have traded close to the deal price, limiting the scope for a large fundamental-driven reaction. Still, a meaningful earnings surprise, a shift in full-year guidance, or fresh details on the transaction timeline could affect near-term trading. Key risks include the pace of EXPAREL demand, potential cost pressures, and any management commentary on integration.
Looking Ahead
The dominant catalyst remains the expected close of the Viatris acquisition before the end of November 2026. Viatris has indicated the deal should be immediately accretive to its 2027 financials, with more than $50 million in annual cost synergies targeted by the end of 2028. On a standalone basis, investors will watch whether Pacira maintains or adjusts its full-year 2026 revenue guidance of $735 million to $760 million. Sustained EXPAREL volume growth, backed by the NOPAIN Act reimbursement pathway and an expanded patent position, continues to underpin the commercial outlook. Pipeline developments, such as the Phase 2 readout for PCRX-201 in knee osteoarthritis, represent additional longer-term opportunities that Viatris plans to advance post-close. Until the transaction completes, the share price is likely to reflect deal value more than quarterly results, although the Q3 report still offers the clearest snapshot of the business being acquired.
Using AI Tools for Deeper Insights
In my own research process, Tickeron’s AI Screener has proven helpful for quickly filtering stocks by technical patterns, fundamentals, and performance metrics to surface relevant comparisons. It allows users to build focused watchlists from thousands of securities without manual effort, which can complement traditional analysis when evaluating names like PCRX ahead of events such as earnings or deal closings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for PCRX turns positive, indicating new upward trend
PCRX saw its Momentum Indicator move above the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 63 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 67 cases where PCRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
PCRX moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PCRX crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +0.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCRX advanced for three days, in 215 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 127 of 188 cases where PCRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for PCRX turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 36 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
PCRX broke above its upper Bollinger Band on October 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.159) is normal, around the industry mean (7.659). PCRX has a moderately high P/E Ratio (104.000) as compared to the industry average of (0.330). Projected Growth (PEG Ratio) (0.684) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.416) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of injectable therapeutic products
Industry PharmaceuticalsGeneric
Advertisement